For decades, prednisone has offered children with Duchenne muscular dystrophy a fragile bargain — steadier muscles at the cost of quietly compromised bones. A new study has now named the biological mechanism behind this trade-off, identifying specific proteins whose suppression reveals how prednisone undermines skeletal formation during the very years a child's bones are most urgently growing. The research also carries a measure of hope: when patients transitioned to an alternative therapy called vamorolone, the suppressed markers recovered, suggesting the harm need not be permanent.
Study identifies how prednisone impairs bone health in children with muscular dystrophy
Children with Duchenne muscular dystrophy receiving prednisone face impaired bone growth and health, potentially affecting skeletal development during critical childhood years.